PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

被引：0
|
作者：
Yamatani, Kotoko [1 ]
Watanabe, Tatsuro [2 ]
Saito, Kaori [1 ]
Maiti, Abhishek [3 ]
Yamashita, Satoshi [4 ]
Khasawneh, Abdullah [1 ]
Paran, Faith Jessica [5 ]
Hayes, Kala [6 ]
Borthakur, Gautam [6 ]
Harman, Joe R. [7 ]
Kimura, Shinya [8 ]
DiNardo, Courtney D. [6 ]
Milne, Thomas A. [7 ]
Andreeff, Michael [9 ]
Tabe, Yoko [1 ,6 ]
Konopleva, Marina Y. [6 ,10 ,11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Dept Clin Lab Med, Tokyo, Japan
[2] Saga Univ, Dept Drug Discovery & Biomed Sci, Fac Med, Saga, Japan
[3] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[4] Maebashi Inst Technol, Life Engn Dept, Fac Engn, Gunma, Japan
[5] Juntendo Univ, Grad Sch Med, Dept Res Support Utilizing Bioresource Bank, Tokyo, Japan
[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[7] Univ Oxford, MRC Weatherall Inst Mol Med, Radcliffe Dept Med, MRC Mol Haematol Unit, Oxford, England
[8] Saga Univ, Div Hematol Resp Med & Oncol, Dept Internal Med, Saga, Japan
[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[10] Montefiore Med Ctr, Dept Oncol, Bronx, NY USA
[11] Albert Einstein Coll Med, Bronx, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178554
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [32] Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
    Klocke, Heather
    Dong, Zhao Ming
    O'Brien, Craig
    Burwick, Nicholas
    Richard, Robert E.
    Wu, Daniel Y.
    Chauncey, Thomas R.
    Graf, Solomon A.
    CASE REPORTS IN HEMATOLOGY, 2020, 2020
  • [33] Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
    Shoumariyeh, Khalid
    Jung, Johannes
    Rassner, Michael
    Dold, Sandra Maria
    Riebl, Veronika
    Pantic, Milena
    Herget, Georg
    Marks, Reinhard
    Lubbert, Michael
    Wasch, Ralph
    Engelhardt, Monika
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1637 - 1640
  • [34] Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia
    Manda, Sudhir
    Anz, Bertrand
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte
    Renshaw, John
    Geils, George F.
    Cruz, Jose
    Fanning, Suzanne
    Melear, Jason
    Sharman, Jeff P.
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Donnellan, William
    BLOOD, 2021, 138
  • [35] CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia
    Simpson, Haley M.
    Novak, Amanda
    Danis, Catherine
    Yarnell, Michael
    Duong, Phoebe
    Stevens, Brett M.
    Jordan, Craig T.
    Kohler, M. Eric
    BLOOD, 2024, 144 : 3416 - 3417
  • [36] Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax
    Culp-Hill, Rachel
    Stevens, Brett M.
    Jones, Courtney L.
    Pei, Shanshan
    Dzieciatkowska, Monika
    Minhajuddin, Mohammad
    Jordan, Craig T.
    D'Alessandro, Angelo
    METABOLITES, 2023, 13 (04)
  • [37] Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
    Daniel A. Pollyea
    Brett M. Stevens
    Courtney L. Jones
    Amanda Winters
    Shanshan Pei
    Mohammad Minhajuddin
    Angelo D’Alessandro
    Rachel Culp-Hill
    Kent A. Riemondy
    Austin E. Gillen
    Jay R. Hesselberth
    Diana Abbott
    Derek Schatz
    Jonathan A. Gutman
    Enkhtsetseg Purev
    Clayton Smith
    Craig T. Jordan
    Nature Medicine, 2018, 24 : 1859 - 1866
  • [38] Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
    Pollyea, Daniel A.
    Stevens, Brett M.
    Jones, Courtney L.
    Winters, Amanda
    Pei, Shanshan
    Minhajuddin, Mohammad
    D'Alessandro, Angelo
    Culp-Hill, Rachel
    Riemondy, Kent A.
    Gillen, Austin E.
    Hesselberth, Jay R.
    Abbott, Diana
    Schatz, Derek
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Smith, Clayton
    Jordan, Craig T.
    NATURE MEDICINE, 2018, 24 (12) : 1859 - +
  • [39] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Li-xia Zhu
    Rong-rong Chen
    Lu-lu Wang
    Jia-nai Sun
    De Zhou
    Li Li
    Jie-jing qian
    Yi Zhang
    Hong-yan Tong
    Wen-juan Yu
    Hai-tao Meng
    Wen-yuan Mai
    Wan-zhuo Xie
    Jie Jin
    Xiu-jin Ye
    Hong-hu Zhu
    Supportive Care in Cancer, 2022, 30 : 7031 - 7038
  • [40] Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report
    Paredes, Hanrry Jerry
    Francisco Gonzalez, M.
    BLOOD, 2019, 134
12345